Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Rybelsus is the first oral GLP-1 and is made by Novo Nordisk. This drug contains semaglutide, the active ingredient in ...

Spending on Ozempic, Wegovy and other similar prescriptions soared 500 percent in five years, according to a research letter.

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

The apparent success — and now almost ever-present ubiquity — of GLP-1 receptor agonists in weight loss has led to research, and possible uses, far beyond its initial indications in diabetes, ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), is back in the green ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

notes that the GLP-1 pill Rybelsus is already available, but only approved by the U.S. Food and Drug Administration (FDA) for diabetes treatment and not obesity. Orforglipron is aimed specifically ...

The pharma giant said its oral GLP-1 drug demonstrated significant efficacy results and a safety profile consistent with its ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Lexaria Bioscience (LEXX) provides a glucagon-like peptide-1 strategic update following important industry developments reported both by Pfizer ...

Americans spent an estimated $71.7 billion on GLP-1 drugs including Ozempic and Wegovy in 2023, a 500 percent increase from their spending on such drugs five years earlier, according to a research ...